GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » Cyclically Adjusted Book per Share

CYTK (Cytokinetics) Cyclically Adjusted Book per Share : $0.64 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cytokinetics's adjusted book value per share for the three months ended in Mar. 2025 was $-2.235. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.64 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Cytokinetics's average Cyclically Adjusted Book Growth Rate was -34.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -27.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -22.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Cytokinetics was -10.50% per year. The lowest was -27.00% per year. And the median was -20.10% per year.

As of today (2025-05-18), Cytokinetics's current stock price is $31.00. Cytokinetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $0.64. Cytokinetics's Cyclically Adjusted PB Ratio of today is 48.44.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cytokinetics was 82.95. The lowest was 0.70. And the median was 6.49.


Cytokinetics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Cytokinetics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Cyclically Adjusted Book per Share Chart

Cytokinetics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.22 1.95 1.67 1.13 0.76

Cytokinetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.93 0.87 0.76 0.64

Competitive Comparison of Cytokinetics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Cytokinetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Cyclically Adjusted PB Ratio falls into.


;
;

Cytokinetics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cytokinetics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-2.235/134.9266*134.9266
=-2.235

Current CPI (Mar. 2025) = 134.9266.

Cytokinetics Quarterly Data

Book Value per Share CPI Adj_Book
201506 1.933 100.684 2.590
201509 1.737 100.392 2.335
201512 1.733 99.792 2.343
201603 1.462 100.470 1.963
201606 1.228 101.688 1.629
201609 2.055 101.861 2.722
201612 2.321 101.863 3.074
201703 2.197 102.862 2.882
201706 3.274 103.349 4.274
201709 2.730 104.136 3.537
201712 2.036 104.011 2.641
201803 1.844 105.290 2.363
201806 1.376 106.317 1.746
201809 0.953 106.507 1.207
201812 0.474 105.998 0.603
201903 0.061 107.251 0.077
201906 -0.084 108.070 -0.105
201909 -0.336 108.329 -0.418
201912 -0.185 108.420 -0.230
202003 -0.769 108.902 -0.953
202006 -1.303 108.767 -1.616
202009 2.119 109.815 2.604
202012 1.597 109.897 1.961
202103 0.948 111.754 1.145
202106 0.229 114.631 0.270
202109 2.971 115.734 3.464
202112 2.876 117.630 3.299
202203 1.359 121.301 1.512
202206 1.297 125.017 1.400
202209 -0.169 125.227 -0.182
202212 -1.138 125.222 -1.226
202303 -2.395 127.348 -2.538
202306 -3.472 128.729 -3.639
202309 -4.559 129.860 -4.737
202312 -3.801 129.419 -3.963
202403 -3.781 131.776 -3.871
202406 0.924 132.554 0.941
202409 -0.118 133.029 -0.120
202412 -1.145 133.157 -1.160
202503 -2.235 134.927 -2.235

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Cytokinetics  (NAS:CYTK) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cytokinetics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=31.00/0.64
=48.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cytokinetics was 82.95. The lowest was 0.70. And the median was 6.49.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cytokinetics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytokinetics Business Description

Industry
Traded in Other Exchanges
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Executives
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
John T Henderson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Robert I Blum officer: EVP, Corp. Development & CBO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Fady Ibraham Malik officer: SVP Research & Early Dev 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Andrew Callos officer: EVP, Chief Commercial Officers C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Arthur Harrington director C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
B Lynne Parshall director 2855 GAZELLE COURT, CARLSBAD CA 92010
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong officer: VP, Chief Accounting Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw officer: SVP Finance & CFO 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Santo J Costa director
Kaye Edward M. Md director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Mark A Schlossberg officer: SVP - Legal & General Counsel C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg officer: V.P., Human Resources 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080